Mesenchymal Stromal Cells For Acute Respiratory Distress Syndrome

PHASE2CompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

November 26, 2019

Primary Completion Date

March 30, 2024

Study Completion Date

June 30, 2024

Conditions
Respiratory Distress Syndrome, Adult
Interventions
BIOLOGICAL

Human Mesenchymal Stromal Cells

Immediately prior to administration, the study product will be thawed and diluted 1:1 with reconstitution media (1:1 mix of 5% human serum albumin and 10% Dextran 40). Additional reconstitution media is added to a final product volume of 300 mL.

BIOLOGICAL

Cell Reconstitution Media

300 mL of reconstitution media (1:1 mix of 5% human serum albumin and 10% Dextran 40)

Trial Locations (7)

37232

Vanderbilt University Medical Center, Nashville

77030

Memorial Hermann Hospital - Texas Medical Center, Houston

94110

Zuckerberg San Francisco General Hospital and Trauma Center, San Francisco

94143

University of California San Francisco, San Francisco

95817

University of California Davis Medical Center, Sacramento

97239

Oregon Health & Science University, Portland

98112

Harborview Medical Center, Seattle

All Listed Sponsors
collaborator

United States Department of Defense

FED

collaborator

Harborview Injury Prevention and Research Center

OTHER

collaborator

Oregon Health and Science University

OTHER

collaborator

Vanderbilt University Medical Center

OTHER

collaborator

The University of Texas Health Science Center, Houston

OTHER

collaborator

University of Minnesota

OTHER

lead

Michael A. Matthay

OTHER

NCT03818854 - Mesenchymal Stromal Cells For Acute Respiratory Distress Syndrome | Biotech Hunter | Biotech Hunter